Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SGNC Sanguine Corp. Info Thread -- Ignore unavailable to you. Want to Upgrade?

To: FatMatty who wrote (53)	6/24/1998 1:28:00 AM
From: chirodoc	Read Replies (1) \| Respond to of 100

HERE IS WHERE IT ALL BEGAN..JAPAN ......Using the oxygen-carrying, so-called "artificial blood", Fluosol-DA, "developed by us" ........ The operation was performed "quite safely" despite a large blood loss, a stable condition was performed quite safely despite a large blood loss, a stable condition being maintained during and after the operation. Int Surg 1981 Oct;66(4):355-358 Success in the radical resection of esophageal cancer with artificial blood infusion: case report. Mitsuno T, Kawa Y, Kita A, Kohno N Using the oxygen-carrying, so-called "artificial blood", Fluosol-DA, developed by us, we successfully performed a radical resection for esophageal cancer and a one-stage reconstruction, without any blood transfusion. The operation was performed quite safely despite a large blood loss, a stable condition was performed quite safely despite a large blood loss, a stable condition being maintained during and after the operation. Fluosol-DA has no relation to blood type and is stable in a frozen state for one year or more and can, therefore, be used conveniently and safely for treating severe and intraoperative hemorrhages. Furthermore, this preparation may well have at wide application because it greatly reduces the risk of postoperative hepatitis.

To: FatMatty who wrote (53)	6/29/1998 12:48:00 AM
From: chirodoc	Read Replies (1) \| Respond to of 100

NOTICE HOW THEY CHANGED THEIR OPINION OVER TIME Many people remember the heated scientific debate on the possibility of developing an artificial blood substitute based on perfluorocarbons, a debate that spilled over into the mass media. Our journal likewise took part in that debate and, in 1989, published the findings of an interdepartmental commission, approved by the bureau of the Academy's Division of Biochemistry, Biophysics, and the Chemistry of Physiologically Active Compounds. The commission-after analyzing the status, development prospects, and possible applications of domestic per- fluorocarbon emulsions-had stated: "there are thus far no preparations in the country, based on perfluorocar- bon emulsions, suitable for practical use both as a blood substitute-as an oxygen carrier-and as a perfusion fluid. However, the preparation of perfluorocarbon emulsions for organ and tissue perfusion appears highly probable in the very near future." (Vestn. Akad. Nauk SSSR, 1989, no. 6, p. 62). In 1990, work on a perfluoro- carbon blood substitute at the Institute of Theoretical and Experimental Biophysics, suspended in 1985, was resumed. And on February 13, 1996, a registration certificate, no. 96/50/10, was obtained for the Perftoran gas- transporting perfluorocarbon blood substitute. The preparation has been permitted for medical use and indus- trial production in the Russian Federation. This major achievement of science in Russia is the subject of the two following articles by the creators of Perftoran.